Patient P-01319
Synthetic patientNBL-101 · Day 114 · 25–34 · M · baseline S02Steering view · 3DOpen companion preview
Therapy response
Favorable
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
4%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S02
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- GI instability-7
- Treatment adherence+4
- Toxicity+4
- Inflammatory activity-2
- Nutritional resilience+2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion5.4/100
improving · -7.9 vs previous 14 d
Toxicity
Blood11.7/100
worsening · +2.2 vs previous 14 d
Sleep quality
Wearable58/100
improving · +7.1 vs previous 14 d
Energy level
Daily log6.8/10
stable · -0.0 vs previous 14 d
Stress level
Daily log2.6/10
improving · -0.3 vs previous 14 d
Steps
Wearable7,992
improving · +334 vs previous 14 d
Adherence
Companion91.7 %
stable · +0.2 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards restoration · 100 from the failing basin, 15 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
Would not help
- Keep histamine lowGI +7.4 next day on high-intake days · n 17
- Keep fat lowGI +4.5 next day on high-intake days · n 19
- Keep alcohol lowGI +4.3 next day on high-intake days · n 8
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Histamine load+7.4detractor · 95%
- Dietary fat load+4.5detractor · 90%
- Alcohol+4.3detractor · 73%
- Simple carbohydrates-0.8no signal · 15%
- Spicy / capsaicin+0.8no signal · 15%
- Insoluble fibre+0.3no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑75
- DNACYP2D6 poor metabolizer → higher exposure
- DNADPYD *2A → slower clearance
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
- Inflammatory signalling ↓20
- MicrobiomeBacteroides fragilis expansion
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 3.7 · butyrate capacity 79/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 69 ms
- Sleep
- 7.4 h
- Steps
- 8,178
- Resting HR
- 65 bpm
Daily log: GI score 5, nutritional resilience 77, adherence 92.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01766 | 41% | S05 | AD-05 | no change | 90 |
| P-01541 | 23% | S09 | AD-05 | no change | 43 |
| P-01804 | 23% | S19 | AD-05 | improved | 61 |
| P-01329 | 41% | S08 | BR-03 | improved | 79 |
| P-01677 | 40% | S05 | BR-03 | no change | 86 |
| P-01495 | 35% | S07 | BR-03 | improved | 85 |
| P-01468 | 23% | S06 | BR-03 | no change | 41 |
| P-01689 | 23% | S13 | BR-03 | no change | 50 |
| P-01654 | 37% | S08 | CR-01 | improved | 85 |
| P-01479 | 40% | S15 | DT-01 | improved | 84 |
| P-01855 | 35% | S04 | DT-01 | improved | 73 |
| P-01724 | 29% | S10 | DT-01 | improved | 63 |